The Efficacy of Solifenacin Succinate as Adjuvant Therapy for Urinary Tract Infection in Females

Phase 4UnknownNCT02094703

Dr Cipto Mangunkusumo General Hospital126 enrolled

Overview

The efficacy of Solifenacin Succinate 5 mg as adjuvant therapy and levofloxacin (500 mg) for short-term treatment to reduce symptoms in patients with symptomatic non complicated urinary tract infection in females.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

126

Conditions

Urinary Tract Infection

Interventions

LevofloxacinDRUG

Solifenacin succinateDRUG

Placebo (for Solifenacin succinate)DRUG

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * females (18-65 years old) * dysuria in symptomatic non complicated urinary tract infection Exclusion Criteria: * Pediatric Patients (\< 18 years old) * geriatric Patients (\> 65 years old) * pregnant Patients * Patients with complicated urinary tract infection * sexually transmitted infections * Patients with pathological abnormalities in the urinary bladder, including stone/mass * Catheter-mounted * Neurological diseases/disorders * patients with allergy/hypersensitivity with Levofloxacin/Solifenacin

Locations (1)

Cipto Mangunkusumo Hospital

Jakarta, Jakarta Special Capital Region, Indonesia

RECRUITING

Outcomes

Primary Outcomes

Number of participants with storage symptoms

Time frame: up to three days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.